Palatin Technologies Inc.

ASE:PTN  
0.45
+0.01 (+1.38%)
Regulatory, Earnings Announcements

Palatin Technologies Inc Reports First Quarter Fiscal Year 2021 Results And Provides Business Update

Published: 11/17/2020 14:48 GMT
Palatin Technologies Inc (PTN) - Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2021 Results and Provides Business Update.
Q1 Loss per Share $0.02.
From July 25 to Sept 30 Vyleesi Gross Sales $809,100 .
Phase 2 Clinical Results of Pl9643 for Treatment of Dry Eye Disease on Track for December 2020.
Anticipates Filing an Ind & Commencing Clinical Trials With Pl8177 for Non-infectious Uveitis, , in H2 of Calendar Year 2021.
Palatin Technologies -continues Its Work Related to Treatment of Patients With Diabetic Retinopathy, With Ind Filing Targeted for Mid-calendar Year 2021.
Palatin Technologies- to Potentially File an Ind With FDA, Initiate a Clinical Study of Pl8177 for Treatment of Covid-19 Patients Early in Q1 of 2021.